

BIOTOSCANA INVESTMENTS S.A.

Corporate Taxpayer's ID (CNPJ/ME): 19,688,956/0001-56
L-1470 Luxembourg, 70 route d'Esch, Grand-Duché de Luxembourg
Legal representative in Brazil: Av. dos Imarés, 401, São Paulo, SP

NOTICE TO THE MARKET UNIFIED TENDER OFFER

BIOTOSCANA INVESTMENTS S.A. ("**Company**" or "**GBT**") (B3: GBIO33), a leading biopharmaceutical company in Latin America, hereby informs that a draft of the Offer Notice (*Edital*) that was submitted to the Brazilian Securities and Exchange Commission (*Comissão de Valores Mobiliários*) ("**CVM**") related to the Unified Tender Offer process filed by 11718991 CANADA INC., a wholly owned subsidiary of Knight Therapeutics Inc., as informed to the market and GBT's shareholders in the Material Fact disclosed on December 20, 2019, is available at Grupo Biotoscana website – <http://ir.grupobiotoscana.com>. The draft of the Offer Notice (*Edital*) remains subject to CVM's review.

The terms and conditions of the Unified Tender Offer remain as previously disclosed by Knight.

The Company will keep its shareholders and the market informed on the developments of the Unified Tender Offer, in compliance with applicable regulation.

Montevideo, April 1, 2020

BIOTOSCANA INVESTMENTS S.A.

Claudio Coracini
Legal Representative in Brasil

About GBT Grupo Biotoscana

GBT-Grupo Biotoscana (GBT) is a biopharmaceutical group that operates in the fast-growing Latin American region and focuses on rapidly growing market segments such as infectious diseases, oncology and onco-hematology, special treatments, immunology and inflammation and orphan/rare diseases, among others. GBT is currently present throughout 10 Latin American countries where it operates under its companies Biotoscana, United Medical, LKM and DOSA. GBT's strong portfolio combines world-class licenses and proprietary products. To find out more, please visit www.grupobiotoscana.com.

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com.